About Asimov
Asimov is a company based in Boston (United States) founded in 2017. Asimov has raised $209.4 million across 9 funding rounds from investors including Fidelity Investments, CPP Investments and KdT Ventures. The company has 87 employees as of December 31, 2023. Asimov offers products and services including CHO Edge System, LV Edge System, AAV Edge System, and Design Software. Asimov operates in a competitive market with competitors including Amyris, Syngenta, AskBio, Ginkgo Bioworks and Antheia, among others.
- Headquarter Boston, United States
- Employees 87 as on 31 Dec, 2023
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Asimov Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$209.4 M (USD)
in 9 rounds
-
Latest Funding Round
$175 M (USD), Series B
Jan 05, 2023
-
Investors
Fidelity Investments
& 10 more
-
Employee Count
87
as on Dec 31, 2023
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Asimov
Asimov offers a comprehensive portfolio of products and services, including CHO Edge System, LV Edge System, AAV Edge System, and Design Software.
System for producing biologics with high titers.
Enables lentiviral production for therapeutic applications.
Facilitates gene therapy payload design and production.
Cloud-based tool for simulating and optimizing genetic systems.
People of Asimov
Unlock access to complete
Unlock access to complete
Funding Insights of Asimov
Asimov has successfully raised a total of $209.4M across 9 strategic funding rounds. The most recent funding activity was a Series B round of $175 million completed in January 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Asimov
Asimov has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, CPP Investments and KdT Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage investments are made in frontier science ventures.
|
Locked | Locked | Locked | |
|
Investing in Life Sciences sectors like Healthcare and Biotechnology.
|
Locked | Locked | Locked | |
|
Early-stage centric tech-focused VC firm investing in the US
|
Locked | Locked | Locked |
Investor details for Asimov
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Asimov
Investment portfolio details for Asimov
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Asimov
Detailed financials for Asimov
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Asimov Comparisons
Peer comparison for Asimov
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Asimov
Asimov operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Amyris, Syngenta, AskBio, Ginkgo Bioworks and Antheia, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of renewable products for industrial solutions
|
|
| Locked | Locked | Locked |
Crop protection solutions and hybrid seeds are provided for farming.
|
|
| Locked | Locked | Locked |
Gene and protein therapies are developed for treating various diseases.
|
|
| Locked | Locked | Locked |
Gene editing-based cultured ingredients are provided for agriculture.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Synthetic DNA is synthesized via a semiconductor-based platform.
|
Detailed competitors of Asimov
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Asimov
Complete news archive for Asimov
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Asimov
Asimov was founded in 2017.
Asimov is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Asimov is a funded company, having raised a total of $209.4M across 9 funding rounds to date.
As of Dec 31, 2023, the latest employee count at Asimov is 87.
Asimov was founded in 2017 and is headquartered in Boston, United States. An end-to-end platform is offered in the synthetic biology sector, combining computational tools with biological engineering. Engineered host cells, genetic parts libraries, and design software are provided as key components. Cell line development, genetic construct design, and data analysis are enabled through the system, with operations centered on biotechnology applications.
Asimov offers CHO Edge System, LV Edge System, AAV Edge System, and Design Software.
Asimov has 11 investors. Key investors include Fidelity Investments, CPP Investments, KdT Ventures, Casdin Capital, and Pillar VC.